Association of HERV-K and LINE-1 hypomethylation with reduced disease-free survival in melanoma patients

Epigenomics ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 1689-1706
Author(s):  
Maurizio Cardelli ◽  
Remco van Doorn ◽  
Lares Larcher ◽  
Michela Di Donato ◽  
Francesco Piacenza ◽  
...  
Keyword(s):  
Independent Predictor ◽  
Disease Free Survival ◽  
Endogenous Retrovirus ◽  
Human Endogenous Retrovirus ◽  
Free Survival ◽  
Melanocytic Lesions ◽  
Long Interspersed Nuclear Elements ◽  
Melanoma Patients ◽  
And Gender ◽  
Disease Free

Aim: To evaluate CpG methylation of long interspersed nuclear elements 1 (LINE-1) and human endogenous retrovirus K (HERV-K) retroelements as potential prognostic biomarkers in cutaneous melanoma. Materials & methods: Methylation of HERV-K and LINE-1 retroelements was assessed in resected melanoma tissues from 82 patients ranging in age from 14 to 88 years. In addition, nevi from eight patients were included for comparison with nonmalignant melanocytic lesions. Results: Methylation levels were lower in melanomas than in nevi. HERV-K and LINE-1 methylation were decreased in melanoma patients with clinical parameters associated with adverse prognosis, while they were independent of age and gender. Hypomethylation of HERV-K (but not LINE-1) was an independent predictor of reduced disease-free survival. Conclusion: HERV-K hypomethylation can be a potential independent biomarker of melanoma recurrence.

scholarly journals Influence of Sentinel Lymph Node Biopsy on Disease-Free Survival for Melanoma Patients

2014 ◽  
Vol 25 ◽  
pp. iv388
Author(s):  
M. Kukushkina ◽  
S. Korovin ◽  
O. Solodiannikova ◽  
G. Sukach ◽  
A. Palivets ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Disease Free Survival ◽  
Lymph Node Biopsy ◽  
Free Survival ◽  
Node Biopsy ◽  
Melanoma Patients ◽  
Disease Free

Presence of VEGF-R3 in the serum of metastatic malignant melanoma patients: Relationship with clinicobiological parameters

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 18004-18004
Author(s):  
R. Mouawad ◽  
J. Meric ◽  
J. Spano ◽  
D. Khayat ◽  
G. Auclerc ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Disease Free Survival ◽  
Metastatic Malignant Melanoma ◽  
Tumor Burden ◽  
Free Survival ◽  
High Tumor Burden ◽  
Healthy Donors ◽  
Melanoma Patients ◽  
And Gender ◽  
Factor C

18004 Background: The presence of metastases is a strong indicator of poor survival in many types of cancer. It has recently been shown that vascular endothelial growth factor-C (VEGF-C), and its receptor Flt-4 (VEGF-R3) are increased in a variety of tumours and may play a pivotal role in the promotion of metastasis. We previously demonstrated that high soluble VEGF-C level was correlated to high tumor burden. Objectives: This study was designed to i) detect and evaluate whether soluble VEGF-R3 play a role in metastatic malignant melanoma patients ii) to determine if they have any relationship with clinicobiological parameters, clinical response and survivals. Methods: Using a sensitive enzyme-linked immunosorbent assays, VEGF-R3 was retrospectively measured in sera of 60 patients with a fully documented history of melanoma disease in comparison with 30 healthy controls. Disease free survival (DFS) and overall survival (OS) were calculated from the beginning of treatment until either the progression (DFS) or death (OS) and analyzed using the Kaplan-Meier method. Results: Pretreatment circulating VEGF-R3 was detectable in all samples from either melanoma patients or healthy donors. Furthermore, median level of sVEGF-R3 was significantly higher (p = 0.000015) in melanoma patients as compared to healthy donors. (38890 vs 30773 pg/ml respectively). No significant association was noted between sVEGF-R3 levels and gender, age or LDH level. Median serum VEGF-R3 level was significantly higher in patients with high tumor burden as compared to patients with low tumor burden (p = 0.045). The pretreatment sVEGF-R3 level was significantly different (p = 0.025) between responder (n = 27) and non-responding patients (n = 33). Lastly, the relapse-free survival was higher in the group with low sVEGF-R3 concentration compared to the high one’s (14.1 vs 11,9 months) as well as for OS (14.3 Vs 12.6 months) but theses differences were not significant (χ2 = 2,30, p = 0.12 & χ2 = 0.74, p = 0.37 respectively). Conclusion: these results suggest that high pretreatment sVEGF-R3 level is related to bad prognosis in melanoma patients. No significant financial relationships to disclose.

scholarly journals Emergency Presenting Colon Cancer Is an Independent Predictor of Adverse Disease-Free Survival

2015 ◽  
Vol 100 (1) ◽  
pp. 77-86 ◽  
Author(s):  
John Hogan ◽  
Georges Samaha ◽  
John Burke ◽  
Kah Hoong Chang ◽  
Eoghan Condon ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Locoregional Recurrence ◽  
Independent Predictor ◽  
Univariate Analysis ◽  
Disease Free Survival ◽  
Free Survival ◽  
Emergency Presentation ◽  
Colon Cancers ◽  
Analysis Survival ◽  
Disease Free

Abstract Twenty percent of colon cancers present as an emergency. However, the association between emergency presentation and disease-free survival (DFS) remains uncertain. Consecutive patients who underwent elective (CC) and emergent (eCC) resection for colon cancer were included in the analysis. Survival outcomes were compared between the 2 groups in univariate/multivariate analyses. A total of 439 patients underwent colonic resection for colon cancer during the interval 2000−2010; 97 (22.1%) presented as an emergency. eCC tumors were more often located at the splenic flexure (P = 0.017) and descending colon (P = 0.004). The eCC group displayed features of more advanced disease with a higher proportion of T4 (P = 0.009), N2 tumors (P < 0.01) and lymphovascular invasion (P< 0.01). eCC was associated with adverse locoregional recurrence (P = 0.02) and adverse DFS (P < 0.01 ) on univariate analysis. eCC remained an independent predictor of adverse locoregional recurrence (HR 1.86, 95% CI 1.50–3.30, P = 0.03) and DFS (HR 1.30, 95% CI 0.88–1.92, P = 0.05) on multivariate analysis. eCC was not associated with adverse overall survival and systemic recurrence. eCC is an independent predictor of adverse locoregional recurrence and DFS.

Patient Preferences for Adjuvant Interferon Alfa-2b Treatment

2001 ◽  
Vol 19 (3) ◽  
pp. 812-823 ◽  
Author(s):  
Kerry L. Kilbridge ◽  
Jane C. Weeks ◽  
Arthur J. Sober ◽  
Frank G. Haluska ◽  
Craig L. Slingluff ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Disease Free Survival ◽  
Interferon Alfa ◽  
Health States ◽  
Free Survival ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Disease Free ◽  
Adjuvant Interferon

PURPOSE: Although trials of adjuvant interferon alfa-2b (IFNα-2b) in high-risk melanoma patients suggest improvement in disease-free survival, it is unclear whether treatment offers improvement in overall survival. Widespread use of adjuvant IFNα-2b has been tempered by its significant toxicity. To quantify the trade-offs between IFNα-2b toxicity and survival, we assessed patient utilities for health states associated with IFN therapy. Utilities are measures of preference for a particular health state on a scale of 0 (death) to 1 (perfect health).PATIENTS AND METHODS: We assessed utilities for health states associated with adjuvant IFN among 107 low-risk melanoma patients using the standard gamble technique. Health states described four IFNα-2b toxicity scenarios and the following three posttreatment outcomes: disease-free health and melanoma recurrence (with or without IFNα-2b) leading to cancer death. We also asked patients the improvement in 5-year disease-free survival they would require to tolerate IFN.RESULTS: Utilities for melanoma recurrence with or without IFNα-2b were significantly lower than utilities for all IFNα-2b toxicities but were not significantly different from each other. At least half of the patients were willing to tolerate mild-moderate and severe IFNα-2b toxicity for 4% and 10% improvements, respectively, in 5-year disease-free survival.CONCLUSION: On average, patients rate quality of life with melanoma recurrence much lower than even severe IFNα-2b toxicity. These results suggest that recurrence-free survival is highly valued by patients. The utilities measured in our study can be applied directly to quality-of-life determinations in clinical trials of adjuvant IFNα-2b to measure the net benefit of therapy.

scholarly journals Complete Pathologic Response Predicts Disease-Free Survival for Melanoma Patients Undergoing Neoadjuvant Therapy

2021 ◽  
Vol 233 (5) ◽  
pp. S246
Author(s):  
Kristen E. Rhodin ◽  
Elizabeth M. Gaughan ◽  
Vignesh Raman ◽  
April K. Salama ◽  
Brent A. Hanks ◽  
...  
Keyword(s):  
Neoadjuvant Therapy ◽  
Disease Free Survival ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Free Survival ◽  
Melanoma Patients ◽  
Disease Free

Expression of theHCRP1mRNA in HCC as an independent predictor of disease-free survival after surgical resection

2009 ◽  
Vol 39 (2) ◽  
pp. 164-176 ◽  
Author(s):  
Ming-Wei Lai ◽  
Shiu-Feng Huang ◽  
Shi-Ming Lin ◽  
Tse-Ching Chen ◽  
Chun-Yen Lin ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Independent Predictor ◽  
Disease Free Survival ◽  
Free Survival ◽  
Disease Free

Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients

The Surgeon ◽  
2017 ◽  
Vol 15 (6) ◽  
pp. 329-335 ◽  
Author(s):  
Paolo Aurello ◽  
Giammauro Berardi ◽  
Diego Giulitti ◽  
Antonio Palumbo ◽  
Simone Maria Tierno ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Independent Predictor ◽  
Disease Free Survival ◽  
Tumor Stroma ◽  
Free Survival ◽  
Gastric Cancer Patients ◽  
Disease Free

scholarly journals Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

1998 ◽  
Vol 16 (4) ◽  
pp. 1425-1429 ◽  
Author(s):  
H Pehamberger ◽  
H P Soyer ◽  
A Steiner ◽  
R Kofler ◽  
M Binder ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Primary Tumor ◽  
Disease Free Survival ◽  
Interferon Alfa ◽  
Breslow Thickness ◽  
Stage Ii ◽  
Primary Stage ◽  
Free Survival ◽  
Melanoma Patients ◽  
Disease Free

PURPOSE Patients with primary cutaneous melanoma with a Breslow thickness > or = 1.5 mm have only a 30% to 70% probability of survival after surgery, and no adjuvant therapy has so far improved this outcome. Since interferon alfa-2a (IFNalpha2a) exhibits antitumor activity in metastatic melanoma, we investigated whether adjuvant IFNalpha2a diminishes the occurrence of metastases and thus prolongs disease-free survival in melanoma patients after excision of the primary tumor. PATIENTS AND METHODS In a prospective randomized study, 311 melanoma patients with a Breslow thickness > or = 1.5 mm were assigned to either adjuvant IFNalpha2a treatment (n = 154) or observation (n = 157) after excision of the primary tumor. IFNalpha2a was given daily at a dose of 3 mIU subcutaneously (s.c.) for 3 weeks (induction phase), after which a dose of 3 mIU s.c. three times per week was given over 1 year (maintenance phase). RESULTS Prolonged disease-free survival was observed in patients treated with IFNalpha2a versus those who underwent surgery alone. This difference was significant (P = .02) for all patients enrolled onto the study (intention-to-treat analysis) at a mean observation time of 41 months. Subgroup analysis showed that Breslow tumor thickness had no influence on treatment results in the groups of patients investigated. CONCLUSION Adjuvant IFNalpha2a treatment diminishes the occurrence of metastases and thus prolongs disease-free survival in resected primary stage II cutaneous melanoma patients.

Sign in / Sign up

Export Citation Format

Share Document